Latest studies
- Recruiting
Post-Market Clinical Follow Up Study With Navitor Valve
This study is looking at how well a new heart valve called Navitor works after it's been used in patients. It's for people with a condition called aortic stenosis, where a heart valve doesn't open properly, and aims to check its safety and how long it lasts in real-world use.
Aortic StenosisSweden - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast NeoplasmsSweden - Active not recruitingPHASE3
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This study is testing a new medicine, Amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It's looking at how well different doses work and if they're safe, compared to stopping treatment.
Dermatitis AtopicSweden - Active not recruiting
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
This study looks at how well current treatments for severe Von Willebrand Disease (Type 3) work. It observes people already on their usual treatment to see how they manage their condition and how it affects their daily lives.
Von Willebrand Disease, Type 3Sweden - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
This study looks at a new medicine called emicizumab for people with Type 3 Von Willebrand Disease. It compares emicizumab to standard treatments to see if it's safe and helps prevent bleeding.
Von Willebrand Disease, Type 3Sweden - Active not recruitingPHASE2
METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia
This study looks at whether changing your lifestyle and taking a diabetes drug called metformin can help older adults at risk of memory problems stay healthy and independent, and reduce their risk of developing dementia.
Cognitive DeclineCognitive ImpairmentDementiaSweden - RecruitingPHASE3
Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence
This study is looking at a new treatment for fecal incontinence, a condition causing accidental bowel leakage. It uses the patient's own muscle cells to help strengthen the muscles that control bowel movements. It's in the final stages of testing.
Fecal IncontinenceSweden - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
This study is for women with cervical cancer that has spread. It's testing new combinations of medicines (sac-TMT, pembrolizumab, and possibly bevacizumab) to see if they are safe and can help people live longer or stop their cancer from getting worse.
Cervical CancerSweden - RecruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
Chronic Lymphocytic LeukemiaSweden - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskSweden - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
This study is for people with advanced HR+/HER2- breast cancer. It compares a new drug, sacituzumab tirumotecan (alone or with pembrolizumab), against standard chemotherapy, to see which treatment best controls the cancer's growth.
Breast NeoplasmsSweden - RecruitingPHASE3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
This study is testing a new medicine, mezagitamab, for adults with a bleeding condition called ITP. We want to see if it helps keep platelet counts stable. It's given by injection under the skin.
Immune Thrombocytopenic Purpura (ITP)Sweden - RecruitingPHASE2, PHASE3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This study keeps an eye on people who have had a special treatment called gene-modified T-cell therapy for cancer. It aims to check their health and how well the treatment worked over a long time, making sure it's safe and effective.
NeoplasmsSweden - RecruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaSweden - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two medicines, BGB-16673 and pirtobrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when previous treatments haven't worked well enough. It aims to see which medicine is safer and more effective.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaSweden - RecruitingPHASE3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Researchers are studying a new drug called Maridebart Cafraglutide to see if it can help people with heart disease and who are overweight or obese. The goal is to find out if this drug can lower the risk of heart attacks, strokes, and other serious heart problems.
Atherosclerotic Cardiovascular DiseaseOverweightObesitySweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Years
This study is testing a new vaccine to prevent serious infections caused by certain types of E. coli bacteria in adults aged 60 and over who have had urinary tract infections. It compares the vaccine to a dummy treatment.
Invasive Extraintestinal Pathogenic Escherichia coli DiseaseSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
This study is testing a new medicine, BI 456906, for people who are overweight or have obesity. It wants to see if the medicine helps with weight loss and if it's safe. Participants will get either the real medicine or a dummy injection.
ObesitySweden - Ongoing, recruitingTherapeutic use (Phase IV)
Brain effects of hormonal contraceptives. A randomized, double-blind, longitudinal study comparing two combined oral contraceptives (Estetrol/drospirenone vs ethinylestradiol/levonorgestrel).
This study looks at how different hormone birth control pills affect the brain in women. Researchers want to see if specific brain areas change when taking one of two common contraceptive pills, and how this might relate to mood.
ContraceptionSweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
(20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors
This study is testing a new medicine, larotrectinib, for adult patients with certain types of cancer that have a specific genetic change called an 'NTRK fusion'. Doctors want to see how well the medicine shrinks these tumours and if it's safe.
Solid tumors harboring NTRK fusionSweden - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment
This study is testing a new medicine called VRG50635 for people with Amyotrophic Lateral Sclerosis (ALS). It's an early-stage study to see how the medicine works, how much to give, and if it's safe. Both common and inherited forms of ALS are included.
Amyotrophic Lateral SclerosisSweden - Active not recruitingPHASE3
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
This study looks at a new drug, tucatinib, combined with T-DM1 to treat advanced HER2-positive breast cancer. It aims to see if this combination works better than T-DM1 alone for cancer that has spread or can't be removed by surgery.
HER2-positive Breast CancerSweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
This study is looking into a new treatment, JNJ-73763989, for people who have both Hepatitis B and Hepatitis D. It aims to see how well it works, if it's safe, and how the body handles it, compared to a dummy treatment.
Hepatitis B and Hepatitis D Viral Co-infectionSweden - Active not recruitingPHASE3
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This study looks at new drug combinations for stage I-III triple-negative breast cancer that hasn't fully responded to initial treatment. It compares Dato-DXd with or without Durvalumab against standard treatments to see if they're more effective and safe.
Breast CancerSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
This study is testing a new medicine called semaglutide for people with early Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and how safe it is to use.
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeSweden - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
This study looks at a new drug, epcoritamab, combined with standard medicines (R2) for adults with follicular lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this new combination is.
Follicular Lymphoma (FL)Sweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
This study looks at the long-term safety of a new medicine, AV-101, for people with pulmonary arterial hypertension (PAH). It's for those who have already tried AV-101 in a previous study and aims to learn more about how well it's tolerated over time.
Pulmonary Arterial Hypertension (PAH)Sweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR EXT)
This study looks at a medicine called Vericiguat for children with a type of heart failure. It checks how safe the medicine is and if it causes any unwanted effects. This is a follow-up study for those already taking part.
Heart Failure due to Systemic Left Ventricular Systolic DysfunctionSweden - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery
This study is testing a new experimental drug, CC-90010, alongside standard treatments for a type of brain cancer called glioblastoma. It's for adults whose brain tumour has been recently diagnosed and surgically removed, either fully or in part, to see if the new drug can help.
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resectionSweden - RecruitingPHASE3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).
Cardiovascular Disease and Lipoprotein(a)Sweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Sweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis.
This study is testing a new medicine, amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It compares amlitelimab to a dummy medicine (placebo) to see if it improves eczema symptoms like itching and skin clearing.
Dermatitis atopicSweden - RecruitingPhase III
Study evaluating the efficacy of icotrokinra in ulcerative colitis
This study is testing a new medicine, icotrokinra, for ulcerative colitis (UC) in adults and teenagers. It aims to see if icotrokinra can help reduce UC symptoms and keep the disease under control by targeting inflammation.
Ulcerative colitisSweden - AuthorisedTherapeutic exploratory (Phase II)
HEMO trial - A randomized controlled trial of heparin bolus mobilization prior to peripheral hematopoietic cell collection from patients with lymphoma or myeloma
This study looks at whether a blood-thinning medicine called heparin can help people with lymphoma or myeloma donate more blood stem cells. It compares heparin with a salt solution to see if it makes collecting stem cells easier and more successful.
Myelom, LymfomSweden - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerSweden - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A prospective, single-centre, randomised, double-blind, placebo-controlled, phase I, First-In-Human (FIH) trial evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.
This early-stage study is testing a new medicine called IRL757 in healthy people. It's to check if the medicine is safe and how well people tolerate different doses. The goal is to see if it could eventually help with a condition called apathy, which can affect people with certain brain disorders.
Apathy in neurodegenerative disordersSweden - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacokinetics of APC148 in healthy adults.
This study is testing a new medicine, APC148, for the first time in healthy people. We want to see if it's safe, what side effects it might have, and how it moves through the body. This is an early step in finding new ways to treat urinary tract infections (UTIs).
Urinary tract infections (UTIs)/complicated UTI (cUTI)Sweden - RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
Multiple MyelomaSweden - Active not recruitingPHASE2, PHASE3
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
This study looks at new ways to treat medulloblastoma, a type of brain tumour, in children and young people. It aims to find the best treatments based on the tumour's specific characteristics, hoping to improve the chances of recovery with fewer side effects.
Brain TumorsSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
This study is testing a new treatment combination for locally advanced cervical cancer. It compares standard chemotherapy and radiation with the same treatment plus a new drug, pembrolizumab (Keytruda), to see if it helps patients live longer and stops the cancer from growing.
Locally Advanced Cervical CancerSweden - Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
This registry tracks new adult cases of a rare cancer called Epithelioid Hemangioendothelioma (EHE). It aims to better understand the disease, its progression, and how different treatments work, by collecting information from patients across Europe and the UK.
Epithelioid HemangioendotheliomaSarcoma,Soft TissueSweden - Active not recruitingNA
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
This study looks at the best time to have surgery for advanced ovarian cancer. It compares having surgery first, then chemotherapy, versus having some chemotherapy first, then surgery, then more chemotherapy, to see which approach works better.
Ovarian CancerSweden - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisSweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.
This study looks at a new medicine called cabozantinib for young people with a type of bone cancer called osteosarcoma. It compares cabozantinib plus supportive care with supportive care alone to see if it helps stop the cancer from growing.
Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults, OsteosarcomaSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 (depemokimab) compared with mepolizumab or benralizumab
This study looks at a new medicine called depemokimab for severe asthma with high eosinophils. It compares it to existing treatments like mepolizumab and benralizumab over a year to see if it's just as good at preventing asthma attacks and improving control.
Severe asthma with an eosinophilic phenotypeSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaSweden - Recruiting
Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach
This study looks at how a medicine called Carglumic Acid helps people with rare conditions called Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA) over a long time. It gathers information from patient records and talks to patients and their families.
Methylmalonic AcidemiaPropionic AcidemiaSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
This study is looking at a new way to treat AL amyloidosis, a rare condition where unhealthy proteins build up in your body. It compares a new drug called daratumumab with existing treatments to see if it works better and is safe for people newly diagnosed with the condition.
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)Sweden - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia ASweden - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Sweden